Drug intelligence / Profile preview

CLT-004

Development stage: Preclinical
Lead developer: Charlesson
Modality: Small Molecules

Overview

CLT-004 is a small molecule drug initially developed by Charlesson. It is being investigated primarily for its effects in reducing retinal inflammation and vascular leakage, with potential applications in ocular diseases such as age-related macular degeneration (AMD) and diabetic retinopathy. The compound is also associated with broader therapeutic areas including cardiovascular diseases, congenital disorders, and endocrinology/metabolic disease. As of the latest updates, CLT-004 remains in preclinical or early development stages without published clinical trial results or regulatory approvals[1][4].

Beyond the preview

Go deeper on CLT-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CLT-004.

Explore the full profile